TB Drugs in the Pipeline Carl M. Mendel, MD TB Alliance IUATLD Meeting San Antonio, February 24, 2012 TB Alliance • Founded in 2000 • Not-for-profit Product Development Partnership (PDP) headquartered in New York, with office in Pretoria • Entrepreneurial, virtual approach to drug discovery and development • Largest portfolio of TB drug candidates in history GOVERNMENTS PHARMA BIOTECH TB Alliance ACADEMIA INSTITUTES FOUNDATIONS TB Alliance Mission • Develop new, better treatments for TB that are: – – – Faster-acting and less complex Compatible with anti-retrovirals for HIV/AIDS coinfection Active against drug sensitive and drug resistant strains • Ensure that new regimens are affordable, adopted for use, and made widely available • Coordinate and act as catalyst for global TB drug discovery and development activities TB Alliance Portfolio Discovery TARGET OR CELL-BASED SCREENING Natural Products IMCAS Preclinical Development LEAD IDENTIFICATION LEAD OPTIMIZATION Whole-Cell Hit to Lead Program GSK Mycobacterial Gyrase Inhibitors GSK THPP Series GSK TB Drug Discovery Portfolio NITD Topoisomerase I Inhibitors AZ/NYMC Gyrase B Inhibitors AZ CLINICAL PHASE II CLINICAL PHASE III TBA-354 U. of Auckland/ U. Ill Chicago PA-824 Novartis Moxifloxacin (+ H, R, Z) Bayer Preclinical TB Regimen Development JHU/U. Ill Chicago TMC207 Tibotec Moxifloxacin (+ R, Z, E) Bayer PA-824/Pyrazinamide Folate Biosynthesis Inhibitors AZ Diarylquinolines Tibotec/U. of Auckland TMC207/Pyrazinamide Whole-Cell Hit to Lead Program AZ Riminophenazines IMM/BTTTRI Energy Metabolism Inhibitors AZ/U. Penn Current first-line TB treatment consists of: isoniazid (H) + rifampicin (R) + pyrazinamide (Z) + ethambutol (E) CLINICAL PHASE I Pyrazinamide Analogs Yonsei RNA Polymerase Inhibitors AZ Novel TB regimen development Clinical Development PA-824/TMC207 PA-824/ Moxifloxacin/ Pyrazinamide TB Drug/Regimen Discovery and Development Process Discovery Compound 1 Single Compound Preclinical Development Phase I EBA Compound 2 Compound 3 Regimen A Drug Candidate Pool Compound 4 Compound 5 Phase II Phase III Regimen Identification Identification of New Drug Candidates Regimen B Regimen C Selection of Potential New Regimens Modes of Action Multiple Targets PA-824 OPC-67683 Cell-Wall Synthesis SQ-109 Bioreduction DNA DNA Gyrase Gatifloxacin Moxifloxacin RNA Polymerase Rifapentine Reactive Species mRNA H ADP + ATP Peptide ATP Synthase TMC-207 Ribosome PNU-100480 AZD-5847 TB Regimen Testing: A New Approach Approach to Novel Regimen Development Use animal model(s) to identify most promising combinations Conduct full preclinical, Phase I and Phase II EBA evaluations of each drug singly Explore drug-drug interactions and, as appropriate, preclinical tox of the combination Take combination (regimen) into clinical development (Phase II, III) NC-001 NC-001: Use of EBA to Test Principles Learned From Animal Models and to Begin Clinical Development of Novel Regimens NC-001 (first novel combination EBA study) – – – – J-Z synergy Pa-Z additivity Pa-J antagonism Pa-M-Z an enhanced novel regimen EBA = early bactericidal activity Pa = PA-824; M = moxifloxacin; Z = pyrazinamide; J = TMC207 First Novel Combo EBA: NC-001 Pa-M-Z Pa-Z-(M pbo) J-Z 2 weeks of treatment J -(Z pbo) J-Pa Rifafour Pa = PA-824: M = moxifloxacin; Z = pyrazinamide; J = TMC207 All Treatment Groups: Bi-linear Regression Mean of LogCFU Over Day; Change from Baseline (Day X – Day 0) 0 -.5 -1 -1.5 -2 -2.5 logCFU change from baseline .5 Bi-linear Regression: logCFU change from baseline 0 2 4 6 8 10 12 14 Day TMC207 TMC207 & PA-824 PA-824 & Pyr & Moxifloxacin TMC207 & Pyrazinamide PA-824 & Pyrazynamide Rifafour e275 All Treatment Groups: Bi-linear Regression Mean of TTP Over Day; Change from Baseline (Day X – Day 0) 200 150 100 0 50 TTP change from baseline Bi-linear regression: TTP change from baseline 0 2 4 6 8 10 12 14 Day TMC207 TMC207 & PA-824 PA-824 & Pyr & Moxifloxacin TMC207 & Pyrazinamide PA-824 & Pyrazynamide Rifafour e275 NC-001 Conclusions • Validation of mouse data: J-Z synergy, Pa-Z additivity, Pa-J antagonism • Pa-M-Z an enhanced novel regimen in 2-wk study – All three compounds contribute to observed effect • EBA can distinguish between treatments – Just as it has previously distinguished between doses • CFU and TTP give similar results Pa = PA-824; M = moxifloxacin; Z = pyrazinamide; J = TMC207 Post NC-001 Study: Next Steps • Develop Pa-M-Z for both DS- and DR-TB (in setting of appropriate resistance testing) – 2-month “SSCC” study (NC-002) as next step – In patients whose M.tb is sensitive to Pa, M, and Z • Build on J-Z and Pa-Z backbones • Explore J-Pa building block • Continue to examine potential regimens in mouse models and bring promising new regimens into clinical development Pa = PA-824; M = moxifloxacin; Z = pyrazinamide; J = TMC207 NC-002: First Study to Examine DS- and MDR-TB Together Using the Same Treatment for Both NC-002 Objectives Pa-M-Z vs Rifafour in DS-TB Pa-M-Z in MDR-TB consistent with Pa-M-Z in DS-TB DS vs MDR in 2-wk EBA 2-wk EBA vs 2-mo “SSCC” Feasibility of multicenter “EBA” study Pa = PA-824; M = moxifloxacin; Z = pyrazinamide First Novel Combo SSCC: NC-002 In patients with M.tb sensitive to Pa, M, and Z Pa(200mg)-M-Z Pa(100mg)-M-Z 2 months of treatment (plus 2-wk EBA substudy) Rifafour Pa(200mg)-M-Z (MDR) Z dose = 1500mg Pa = PA-824; M = moxifloxacin; Z = pyrazinamide Unified DS/DR Development Path Current MDR Development Path Issues Requires separate development program from DS-TB Standard of care (SOC) treatment (control group) for MDR-TB is • Lengthy (24+ months) • Toxicity-prone / difficult • Of limited efficacy • Expensive A new regimen for MDR-TB could be much shorter than SOC, but the timepoint for comparison will still be defined by the SOC control group Unified DS/DR Development Path: Paradigm Shift Indication: “Drugs X, Y, and Z in combination are indicated for the treatment of tuberculosis caused by M.tb strains that are sensitive to drugs X, Y, and Z.” Patients should be treated based on what they are sensitive to--rather than what they are resistant to “MDR” label doesn’t apply in setting of new chemical entities Unified DS/DR Regimen Development Path Complete regimens as good as HRZE SD, MD; DDI if needed Mouse model cidal 2-wk EBA 2-wk Combo EBA sterilizing Dose ranging in cidal Only combos in sterilizing Dose ranging here for single drugs Best doses used in combos Better than HRZE 2-mo SSCC DS + DR sensitive to test regimen All final regimens DS vs HRZE tested here DS only MDR also MDR not randomized Ph3 2-4 mos DS vs HRZE MDR for consistency Coming This Year SQ109 EBA study results PNU100480 EBA study results NC-002 (Pa-M-Z x 2 mos in DS and MDR pts) NC-003 2-wk EBA study examining four new regimens: J-Pa-Z, J-Pa-C, J-Z-C, J-Pa-Z-C TBA-354 (nitroimidazole) FIM study Expansion of biobanking initiative Gatifloxacin Ph 3 results Thank You! And Thank You To Our: Funders Partners Stakeholders Staff Patients TB Alliance Supporters Bill & Melinda Gates Foundation United States Food and Drug Administration European Union United Kingdom Department for International Development United States Agency for International Development